Haematological Malignancies

Treatment toxicity and infectious complications related to immunosuppression drive the risk of organ failure in this population. Adults with haematological malignancies receiving intensive chemotherapy with or without HCT are at high risk of organ failure. Around 15% of newly diagnosed AML patients and 10-20% of allogeneic HCT recipients require ICU admission during treatment. ICU admission in these patients is associated with about 40% in-hospital mortality and up to 60% 1-year mortality.